Home

Atlas Venture Fund VII L P

CIK 1346450 · last filed 2018-07-02

Atlas Venture Fund VII L P is a corporate insider who has filed 3 SEC Form 4 insider transactions across 3 companies since 2010. The most recent filing, for ZFGN, was dated Jul 2, 2018. Across all open-market trades the lifetime net is −$558.4K, making them a net seller over the disclosed history. The firm reports its address in Boston, MA. 6 SEC filings were submitted jointly with Atlas Venture Associates VII, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

3

Lifetime Open-Market Net

-$558.4K

Filer Profile

Reported Address
56 WAREHAM STREET, FLOOR 3
BOSTON, MA 02118
Phone
(617) 588-2694
State of Incorporation
DE
Related Filers
Atlas Venture Associates VII, L.P. — 6 joint filings, latest 2018-07-02
Atlas Venture Associates IX, LLC — same reported address
Atlas Venture Associates VIII, Inc. — same reported address
Atlas Venture Associates VIII, L.P. — same reported address
Atlas Venture Fund IX, L.P. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Larimar Therapeutics, Inc. (ZFGN) Delisted 10%+ Owner 1 — — $0 1 2018-07-02
Zyla Life Sciences (EGLT) Delisted 10%+ Owner 2,460,949 — — $500.0K 1 2014-02-12
Oruka Therapeutics, Inc. (ABIO) Delisted 10%+ Owner 147 $28.80 $4.2K -$1.06M 1 2010-03-31

Recent Filings

3 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2018-07-02 Larimar Therapeutics, Inc. (ZFGN) Delisted Other (J) −4,082,601 $0 EDGAR
2014-02-12 Zyla Life Sciences (EGLT) Delisted Mixed +2,152,222 $2.80M EDGAR
2010-03-31 Oruka Therapeutics, Inc. (ABIO) Delisted Sell (S) −140,000 -$1.06M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.